Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales fréquentes
Nom anglais: Angiotensin II Type 1 Receptor Blockers
Descriptor UI:D047228
Tree Number:D27.505.519.162.500
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales les plus fréquentes",
"headline": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antagonistes du récepteur de type 1 de l'angiotensine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-21",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antagonistes des récepteurs aux angiotensines",
"url": "https://questionsmedicales.fr/mesh/D057911",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes des récepteurs aux angiotensines",
"code": {
"@type": "MedicalCode",
"code": "D057911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.162"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II",
"alternateName": "Angiotensin II Type 1 Receptor Blockers",
"code": {
"@type": "MedicalCode",
"code": "D047228",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tadashi Namisaki",
"url": "https://questionsmedicales.fr/author/Tadashi%20Namisaki",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. tadashin@naramed-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Kosuke Kaji",
"url": "https://questionsmedicales.fr/author/Kosuke%20Kaji",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
},
{
"@type": "Person",
"name": "Naotaka Shimozato",
"url": "https://questionsmedicales.fr/author/Naotaka%20Shimozato",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
},
{
"@type": "Person",
"name": "Yukihisa Fujinaga",
"url": "https://questionsmedicales.fr/author/Yukihisa%20Fujinaga",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37511475",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36894035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.gastro.2023.02.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-023-03202-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal age to stop prostate cancer screening and early detection.",
"datePublished": "2023-08-19",
"url": "https://questionsmedicales.fr/article/37598870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcpo.2023.100443"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36121650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34298"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antagonistes des récepteurs aux angiotensines",
"item": "https://questionsmedicales.fr/mesh/D057911"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II",
"item": "https://questionsmedicales.fr/mesh/D047228"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antagonistes du récepteur de type 1 de l'angiotensine-II - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment diagnostiquer une hypertension ?\nQuels tests pour évaluer l'efficacité des ARA ?\nQuels signes indiquent une insuffisance cardiaque ?\nComment évaluer les effets secondaires des ARA ?\nQuand faire un ECG chez un patient sous ARA ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quels symptômes nécessitent un avis médical urgent ?\nQuels effets secondaires courants des ARA ?\nComment reconnaître une hypotension ?\nQuels symptômes d'une réaction allergique aux ARA ?\nQuels signes d'une hyperkaliémie ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment prévenir l'hypertension ?\nLe tabagisme influence-t-il l'hypertension ?\nL'alcool affecte-t-il la pression artérielle ?\nComment le stress impacte-t-il la santé cardiaque ?\nQuels aliments éviter pour contrôler la pression ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment fonctionnent les ARA ?\nQuels sont les ARA les plus prescrits ?\nQuand débuter un traitement par ARA ?\nLes ARA sont-ils sûrs pendant la grossesse ?\nComment ajuster la dose d'ARA ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quelles sont les complications de l'hypertension ?\nComment l'hypertension affecte-t-elle les reins ?\nQuels risques d'AVC liés à l'hypertension ?\nL'hypertension peut-elle causer des problèmes oculaires ?\nQuels effets de l'hypertension sur le cœur ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quels sont les principaux facteurs de risque d'hypertension ?\nLe diabète influence-t-il l'hypertension ?\nL'hérédité joue-t-elle un rôle dans l'hypertension ?\nLe manque d'exercice est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hypertension ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension est diagnostiquée par des mesures répétées de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des ARA ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pression artérielle et des analyses sanguines pour surveiller les électrolytes sont effectués."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une insuffisance cardiaque ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Essoufflement, fatigue, œdèmes et palpitations peuvent indiquer une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des ARA ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier des symptômes et des tests sanguins pour les électrolytes est nécessaire."
}
},
{
"@type": "Question",
"name": "Quand faire un ECG chez un patient sous ARA ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un ECG est recommandé si le patient présente des symptômes cardiaques ou des anomalies de pression."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un avis médical urgent ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des difficultés respiratoires ou des évanouissements doivent être évalués."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires courants des ARA ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des vertiges, des maux de tête et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypotension ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des étourdissements, une vision floue et une fatigue excessive."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une réaction allergique aux ARA ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Quels signes d'une hyperkaliémie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des palpitations, une faiblesse musculaire et des picotements peuvent signaler une hyperkaliémie."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypertension ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress aident à prévenir l'hypertension."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il l'hypertension ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque d'hypertension et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool affecte-t-il la pression artérielle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut entraîner une augmentation de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Comment le stress impacte-t-il la santé cardiaque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter pour contrôler la pression ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé d'éviter les aliments riches en sodium et en graisses saturées."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les ARA ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA bloquent les récepteurs de l'angiotensine-II, réduisant ainsi la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels sont les ARA les plus prescrits ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA courants incluent le losartan, le valsartan et l'irbésartan."
}
},
{
"@type": "Question",
"name": "Quand débuter un traitement par ARA ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement par ARA est débuté lorsque d'autres antihypertenseurs sont inefficaces ou mal tolérés."
}
},
{
"@type": "Question",
"name": "Les ARA sont-ils sûrs pendant la grossesse ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA sont généralement contre-indiqués pendant la grossesse en raison de risques pour le fœtus."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose d'ARA ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose est ajustée en fonction de la réponse du patient et des effets secondaires observés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hypertension ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et les lésions rénales."
}
},
{
"@type": "Question",
"name": "Comment l'hypertension affecte-t-elle les reins ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension peut endommager les vaisseaux sanguins des reins, entraînant une insuffisance rénale."
}
},
{
"@type": "Question",
"name": "Quels risques d'AVC liés à l'hypertension ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension augmente le risque d'accident vasculaire cérébral ischémique et hémorragique."
}
},
{
"@type": "Question",
"name": "L'hypertension peut-elle causer des problèmes oculaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des lésions rétiniennes et des problèmes de vision."
}
},
{
"@type": "Question",
"name": "Quels effets de l'hypertension sur le cœur ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertrophie du cœur, des arythmies et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'hypertension ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et une alimentation riche en sodium."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il l'hypertension ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète augmente le risque d'hypertension et de complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans l'hypertension ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hypertension augmentent le risque individuel."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire contribue à l'augmentation de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes de santé."
}
}
]
}
]
}
The central objective of the metamorphosis of discovery science into biomedical applications is to serve the purpose of patients and curtail the global disease burden. The journey from the discovery o...
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv...
The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro...
In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo...
EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....
Cancer therapy-induced cardiotoxicity is an emerging clinical and healthcare issue. Myocardial dysfunction and heart failure are mostly responsible for increased cardiovascular mortality in cancer dis...
Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can...
We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer...
Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the...
Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and ...
The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can...
This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ...
In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst...
Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o...
In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me...
This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv...
Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...
Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers a...
A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. ...
Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir...
This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ...
Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings....
NCT05541601....